Thus, some authors have suggested the use of angiotensin-converting enzyme inhibitors to modulate RAS, favoring the production of angiotensin 1–7, thus contributing to the change in body composition and preventing the development of sarcopenia and simultaneously ameliorating the MetS pathophysiologic parameters [108,196,197,198]. This evidence concerns the gene AGT and metabolic syndrome.